Clinical Trials Logo

Human Immunodeficiency Virus (HIV) clinical trials

View clinical trials related to Human Immunodeficiency Virus (HIV).

Filter by:

NCT ID: NCT03577470 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

An Italian Observation of Antiretroviral Treatment in Participants Taking Darunavir/ Cobicistat Plus Emtricitabine and Tenofovir Alafenamide Fumarate

DIAMANTE
Start date: June 13, 2018
Phase:
Study type: Observational

The purpose of this study is to describe the effectiveness of Darunavir/ Cobicistat/ Emtricitabine/ Tenofovir Alafenamide (D/C/F/TAF), measured as virological response at Week 48 as per Food and Drug Administration (FDA) snapshot algorithm through collection of daily practice data in the Italian setting.

NCT ID: NCT03489421 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Mitochondria in HIV and Aging (MITO+)

(MITO+)
Start date: July 15, 2018
Phase:
Study type: Observational

Older adults with human immunodeficiency virus (HIV) and a long history of antiretroviral therapy have more mitochondrial dysfunction- the cells that help them make energy. This dysfunction in mitochondria may lead to symptoms of muscle fatigue, physical function impairment, and impaired exercise tolerance compared to HIV-uninfected controls of a similar age and body mass index (BMI). Furthermore, the investigators hypothesize that the older antiretroviral therapy (ART) of tenofovir disoproxil fumarate (TDF) is associated with greater impairment in mitochondrial function than the newer agent, tenofovir alafenamide (TAF).

NCT ID: NCT03407105 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

A Dose-Escalation Study of MDX-010 Administered Monthly as Immunotherapy in Subjects Infected With Human Immunodeficiency Virus (HIV)

Start date: April 21, 2003
Phase: Phase 1
Study type: Interventional

The purpose of this study is to assess the safety and tolerability of 2 or 4 doses of MDX-010 in HIV-infected subjects

NCT ID: NCT03290755 Recruiting - Hepatitis c Clinical Trials

Sexual Hepatitis C in HIV Positive Men Who Have Sex With Men (MSM) in Bordeaux

HEPCSEX
Start date: November 8, 2017
Phase: N/A
Study type: Observational

The main objective of this study is to analyse sexual behavior of HIV + MSM in Bordeaux, who have sexually contracted hepatitis C between January 1st 2013, to January 31, 2017. These data will bring some improvement about prevention and maybe reduced the hepatitis C incidence.

NCT ID: NCT02974998 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Expanding HIV Testing and Prevention to Reach Vulnerable Young Women

Start date: November 2016
Phase: N/A
Study type: Interventional

This two-arm cluster randomized trial is testing a gender-focused comprehensive HIV testing and counselling (HTC) program, the Young Women's Health CoOp (YWHC) with a standard HTC program and will target female adolescents (aged 16-19) who use substances and have dropped out of school. To evaluate the process, the study will examine the feasibility of using peer role models as recruiters and co-facilitators of the intervention and monitor fidelity to the intervention. Efficacy of the intervention on behavioral and biological outcomes, and on linkages to health services, through follow-up visits conducted 6- and 12-months post-enrollment will be also assessed.

NCT ID: NCT02965014 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

NC Young Women's CoOp

Start date: January 18, 2017
Phase: N/A
Study type: Interventional

This three-arm cross-over cluster-randomized trial will develop, test, and compare the efficacy of two delivery formats of the Women's CoOp (WC), which is designed to provide risk reduction and empowerment skills, as well as linkages to healthcare services for substance-using women. The current study will develop a revised version of the WC and evaluate the relative efficacy of a face-to-face (face-to-face WC), mobile Health application (mHealth WC) delivery format, and HIV counseling and testing (HCT) as a control to reduce risky sexual behaviors, reduce substance use, and increase sexual negotiation among young (18-25 years) substance-using African American women who are sexually active and have not recently been tested for HIV in three NC counties.

NCT ID: NCT02873741 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

New Strategies to Assess Anal Cancer Risk In Women

ANCAR-WIHS
Start date: July 2016
Phase: N/A
Study type: Interventional

The purpose of this research is to study different strategies to identify women at highest risk for anal cancer. Primarily, investigators want to study a risk assessment called the Anal Cancer Risk Index; it gives women an overall number score based on risk factors that they may have for anal cancer, such as age, number of sexual partners, or smoking. Investigators seek to understand whether women with higher Anal Cancer Risk Index scores are more likely to have abnormal results on anal pap smears, HPV tests, or anal biopsies. The study team will collect swabs of the cervix and the anus to study different laboratory tests that could identify women at highest risk of cervical and anal cancer. These laboratory tests include an anal pap smear, tests for markers of disease and tests that detect the HPV types most likely to cause cancer. The study team would like to see which of these laboratory tests do the best job at predicting precancerous lesions in the anus and are better indicators of risk for cancer. After collecting these swabs, women will have a procedure called high resolution anoscopy where investigators look closely at the anus and biopsy any suspicious areas. Finally, the study team will look for HPV proteins and changes that HPV can make in cells to see if these tests predict anal lesions.

NCT ID: NCT02850016 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

Romidepsin Plus 3BNC117 Phase 2a Study

ROADMAP
Start date: January 6, 2017
Phase: Phase 2
Study type: Interventional

The aim of this protocol is to evaluate the effects of romidepsin plus 3BNC117 or romidepsin alone on delaying or preventing viral rebound in ART-treated HIV-1-infected individuals during an analytical interruption of ART.

NCT ID: NCT02825797 Recruiting - Clinical trials for Human Immunodeficiency Virus (HIV)

3BNC117 and 10-1074 in HIV-infected Individuals

Start date: June 2016
Phase: Phase 1
Study type: Interventional

This is a phase 1b clinical trial to evaluate the safety, pharmacokinetics and the antiretroviral effects of the combination of two anti-human immunodeficiency virus (HIV) broadly neutralizing antibodies, 3BNC117 and 10-1074, administered intravenously in HIV-infected individuals. This study is intended to support the development of the combination of 3BNC117 and 10-1074 mAbs for use in the treatment of HIV-1 infection.

NCT ID: NCT02572401 Completed - Clinical trials for Human Immunodeficiency Virus (HIV)

Steering Together in a New Direction: Reducing the Risk of HIV/STD Among African American Men

STAND
Start date: October 2011
Phase: N/A
Study type: Interventional

African American men have by far the highest rates of HIV in the US, but there are few randomized controlled trials (RCTs) of interventions to dissuade heterosexually active African American men from engaging sexual risk behavior. This research seeks to address this gap in the behavioral intervention literature. That self-initiated behavior change, as well as intervention-induced behavior change, is often short-lived, eroding over time, is widely known; accordingly, this research also seeks to test a strategy to sustain intervention efficacy. In a RCT, African American men 18 to 45 years reporting recent unprotected intercourse with a woman will be randomized to the Steering Together in a New Direction (STAND) HIV Risk Reduction Intervention or a No-Intervention Control Condition. To test a strategy to sustain intervention effects, the men also will be randomized to receive or not receive individually tailored text messages. The theoretical basis of the interventions is social cognitive theory and the reasoned action approach, which is an extension of the theory of planned behavior and the theory of reasoned action. Men will complete self-report measures via audio computer-assisted self-interviewing at baseline and immediately post and 6 and 12 months post-intervention. The trial will test whether the STAND HIV Risk Reduction Intervention as compared with the No-Intervention Control Condition, increases consistent condom use, the primary outcome. Secondary outcomes include unprotected intercourse, multiple sexual partners, insertive anal intercourse, and proportion condom-protected intercourse. The trial will also test whether STAND's efficacy is greater among men in the Text Messaging Intervention compared with men not receiving text messages. This will provide information on the utility of a low-cost strategy to extend an intervention's efficacy. Finally, the study will test for mediation of intervention effects: the hypothesis that STAND affects outcome expectancies and self-efficacy, which, in turn, affect consistent condom use.